HT
CPRX

Headlands Technologies’s Catalyst Pharmaceutical CPRX Stock Holding History

Headlands Technologies’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,737
Closed -$188K – 1236
2025
Q1 		$188K Buy
+7,737
New +$174K 0.02% 466
2024
Q4 		– Sell
-271
Closed -$5.39K – 1259
2024
Q3 		$5.39K Buy
+271
New +$5.02K ﹤0.01% 1059
2024
Q2 		– Sell
-9,675
Closed -$154K – 1212
2024
Q1 		$154K Buy
+9,675
New +$146K 0.04% 438

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Headlands Technologies's CPRX Position: Q2 2025 in Review

Headlands Technologies sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 7,737 shares — an estimated $188K sold.

Headlands Technologies first reported a position in CPRX in Q1 2024 and held it in 3 quarters. The position peaked at $188K in Q1 2025. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

  • Headlands Technologies reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Headlands Technologies sold 7,737 Catalyst Pharmaceutical shares in Q2 2025, an estimated $188K.
  • Headlands Technologies first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 3 quarters.
  • Headlands Technologies's Catalyst Pharmaceutical position peaked at $188K in Q1 2025.
  • 365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on Headlands Technologies's 13F filing for Q2 2025, filed 14 Aug 2025.